Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 0.51 |
| ▸ | HTR2B | P41595 | 5/20 | 0.49 |
| ▸ | DRD2 | P14416 | 4/20 | 0.49 |
| ▸ | HTR2C | P28335 | 4/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | HTR1D | P28221 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 1/20 | 0.49 |
| ▸ | KHK | P50053 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1136468 | 0.84 | HTR6 (0.64) | HTR6HTR2BDRD2HTR2CHTR1A | |
| SCHEMBL5203209 | 0.81 | HTR6 (0.57) | HTR6HTR2BDRD2HTR2CHTR1A | |
| SCHEMBL5201144 | 0.78 | HTR6 (0.62) | HTR6DRD2HTR2CHTR1AHTR1D | |
| SCHEMBL5202829 | 0.78 | HTR6 (0.57) | HTR6CYP3A4 | |
| SCHEMBL5200370 | 0.78 | HTR6 (0.53) | HTR6HTR2BDRD2HTR2CHTR1A | |
| SCHEMBL1136427 | 0.77 | HTR6 (0.51) | HTR6HTR2BDRD2HTR2CHTR1A | |
| SCHEMBL5200846 | 0.77 | HTR6 (0.67) | HTR6HTR2BDRD2HTR2CHTR1A | |
| SCHEMBL5971931 | 0.77 | HTR6 (0.59) | HTR6CYP3A4 | |
| SCHEMBL5200506 | 0.77 | PIM1 (0.47) | HTR6HTR2BDRD2HTR2CHTR1A | |
| SCHEMBL5201309 | 0.75 | HTR1D (0.51) | HTR6HTR2BDRD2HTR2CHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401813-B1 | NEW INDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | HOFFMANN LA ROCHE (CH) | 2007-02-07 | — | — | EP | disclosed |
| US-20050171118-A1 | New indole derivatives with 5-HT6 receptor affinity | BEARD COLIN C (US) | 2005-08-04 | — | — | US | disclosed |
| US-20040248902-A1 | New indole derivatives with 5-HT6 receptor affinity | BEARD COLIN CHARLES (US) | 2004-12-09 | — | — | US | disclosed |
| US-6787535-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; PARKINSON'S DISEASE, HUNTINGTON'S DISEASE; PSYCOLOGICAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-09-07 | — | — | US | disclosed |
| EP-1401813-A1 | NEW INDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | F. Hoffman-la Roche AG (CH) | 2004-03-31 | — | — | EP | disclosed |
| US-20030073700-A1 | New indole derivatives with 5HT6 receptor affinity | SYNTEX (U.S.A.) LLC, NAME CHANGE TO ROCHE PALO ALTO LLC | 2003-04-17 | — | — | US | disclosed |
| WO-2002098857-A1 | NEW INDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248902-A1 | New indole derivatives with 5-HT6 receptor affinity | HTR6, HTR5A, HTR7 | HTR6 1/4885HTR2B 15/4885DRD2 39/4885 |
| US-20050171118-A1 | New indole derivatives with 5-HT6 receptor affinity | HTR6, HTR5A, HTR7 | HTR6 1/4885HTR2B 11/4885DRD2 35/4885 |
| US-20030073700-A1 | New indole derivatives with 5HT6 receptor affinity | HTR6, HTR5A, HTR7 | HTR6 1/4885HTR2B 13/4885DRD2 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.